tr 987

Small moleculeexperimental

Clinical trial activity

3 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0

Earliest trial started Nov 1, 2016 (NCT03154619)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • tr 987

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06707090Phase 3Nov 30, 2024Turning Point Therapeutics
NCT06707103Phase 3Nov 30, 2024Turning Point Therapeutics
NCT03154619Phase 2Nov 1, 2016SerenaGroup, Inc., Turning Point Therapeutics
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Turning Point TherapeuticsFor profit3222016
SerenaGroup, Inc.For profit1112016
2 organizations
Page 1 / 1